Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ImmunityBio (IBRX) EBT (2016 - 2026)

ImmunityBio has reported EBT over the past 12 years, most recently at -$62.1 million for Q4 2025.

  • Quarterly EBT fell 4.92% to -$62.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$351.6 million through Dec 2025, up 15.0% year-over-year, with the annual reading at -$351.6 million for FY2025, 15.0% up from the prior year.
  • EBT was -$62.1 million for Q4 2025 at ImmunityBio, up from -$67.3 million in the prior quarter.
  • Over five years, EBT peaked at -$59.2 million in Q4 2024 and troughed at -$233.5 million in Q4 2023.
  • The 5-year median for EBT is -$95.2 million (2022), against an average of -$105.8 million.
  • Year-over-year, EBT crashed 115.58% in 2023 and then surged 74.65% in 2024.
  • A 5-year view of EBT shows it stood at -$91.6 million in 2021, then decreased by 18.28% to -$108.3 million in 2022, then crashed by 115.58% to -$233.5 million in 2023, then surged by 74.65% to -$59.2 million in 2024, then dropped by 4.92% to -$62.1 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's EBT are -$62.1 million (Q4 2025), -$67.3 million (Q3 2025), and -$92.3 million (Q2 2025).